Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07610473 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
A Phase 2 study, sponsored by Draig Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT07610473: Recruiting Phase 2 study, sponsored by Draig Therapeutics.
NCT07610473 is a Phase 2 study that is actively recruiting participants, run by Draig Therapeutics. The registered enrollment target is 118 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07610473, a Phase 2 study, is actively recruiting participants, sponsored by Draig Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo looks the drug but contains no medicine. Subjects will attend the clinic for complete general health checks and to complete questionnaires.
Interventions
- DRUG Placebo
- DRUG DT-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2026-05 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
What NCT07610473 shows while recruiting
NCT07610473 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07610473 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07610473 about?
NCT07610473 is a clinical study titled "A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression". In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo lo...
What is the current status of trial NCT07610473?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2026-05. Estimated completion is 2027-05.
What interventions are being tested in trial NCT07610473?
The interventions under investigation include: Placebo (DRUG), DT-101 (DRUG).
Who is sponsoring clinical trial NCT07610473?
This trial is sponsored by Draig Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07610473's enrollment target sits among peer trials
118 618th of 2000 higher than 1,378 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia